Interestingly, depletion of CD4+ T cells completely abrogated the anti-tumor efficacy of the class II HER2-DC1 alone or in combination with anti-PD-1 therapy suggesting the crucial role of CD4+ T cells. This evidence concerns the gene ZDHHC4 and neoplasm.